Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors.
about
Biomarker-Based Approaches for Assessing Alcohol Use DisordersCommon Variants of the Prostaglandin-Endoperoxide Synthase 2 Gene and Hepatocellular Carcinoma SusceptibilityGenome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.Is liver biopsy still needed in children with chronic viral hepatitis?Schistosomiasis does not affect the outcome of HCV infection in genotype 4-infected patientsCare of the liver transplant patient.Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans.Distinct features in natural history and outcomes of acute hepatitis C.CD4+ T-lymphocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infectionIL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population.Ethanol and liver: recent insights into the mechanisms of ethanol-induced fatty liverInterferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?Liver stiffness measurement among patients with chronic hepatitis B and C: results from a 5-year prospective study.FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.Assessment of immunological changes in Epstein-Barr virus co-infection in Egyptian chronic HCV patients.Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.Viral hepatocarcinogenesis.Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients.Evidence-based clinical guidelines for immigrants and refugees.The history of the "natural history" of hepatitis C (1968-2009).Molecular and contextual markers of hepatitis C virus and drug abuse.IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection.Diabetes and Hepatitis C: A Two-Way Association.HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV.Liver Fibrosis Regression Measured by Transient Elastography in Human Immunodeficiency Virus (HIV)-Hepatitis B Virus (HBV)-Coinfected Individuals on Long-Term HBV-Active Combination Antiretroviral Therapy.γ-H2AX+CD8+ T lymphocytes cannot respond to IFN-α, IL-2 or IL-6 in chronic hepatitis C virus infectionPNPLA3 rs738409 Polymorphism Associated with Hepatic Steatosis and Advanced Fibrosis in Patients with Chronic Hepatitis C Virus: A Meta-Analysis.Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression.Distribution of Hepatitis C Risk Factors and HCV Treatment Outcomes among Central Canadian AboriginalThe clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study.From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence.Fibrosis in Chronic Hepatitis C: Correlation between Immunohistochemically-Assessed Virus Load with Steatosis and Cellular Iron ContentRole of IL28-B Polymorphism (rs12979860) on Sustained Virological Response to Pegylated Interferon/Ribavirin in Iranian Patients With Chronic Hepatitis C.Polymorphisms of α1-antitrypsin and Interleukin-6 genes and the progression of hepatic cirrhosis in patients with a hepatitis C virus infection.Biomarkers of alcohol consumption and related liver disease.Current therapies for chronic hepatitis C.What is expected from the pathologist in the diagnosis of viral hepatitis?Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis.
P2860
Q26772931-BC069B48-5C47-418C-BDE2-9FC9000BD5E5Q26786180-F78A0C32-0FA5-42DE-9CF9-5E54B5948313Q29417113-31E5EDC4-F3D0-4EE6-BAA0-48855012C4D2Q30250088-DF15DDFF-8402-4B48-BF48-C52DA1C0AED1Q30398796-3D0E2CA2-E357-4CED-A736-48CC8C0A0B99Q33588479-C7D00C96-083F-42F4-9B1F-9F7DCCE44557Q33810193-62075AC1-ECF5-4569-AEDD-1579135D4A8AQ33943907-5509ED1F-D203-4E70-B738-179FEADB3290Q33955210-2C49FDEB-DB44-4F19-8045-C8A14D865C65Q34032909-EB3E8A0D-E98F-47CC-8C39-5C9EDC4E23E4Q34287407-0C763C70-02BC-4E1D-96A8-BF59865D7A6EQ34405039-7668BA24-DF13-49CF-B584-B1AD556C4C37Q34424151-19F5B921-26BE-4235-8C20-999809953C09Q34450720-BD2F2818-CF64-493A-B55B-EBB8629D1937Q34474404-2CB5D259-C7F4-4F92-8A2A-ACC6FE90EC04Q34548411-FCBDB2D4-A321-4620-8C59-88F636833AF0Q34589830-CEABD32E-54AE-4B8C-A027-D1C13EEBE917Q34617749-50C5BE97-76CB-45D7-B9FB-682EDC2CE50CQ34677180-B64C6009-F004-4B64-84FF-A67B6E3F995CQ34749550-62705575-2B4B-4720-8E5D-D1F47FB048D9Q35201293-B01A6EF4-8961-4537-8D79-77B8783C750DQ35216592-67F8D1F9-59A2-4894-9FCC-C51DA23F635BQ35660841-F45FA206-12D8-41E1-839D-941042EF60D5Q35930570-7D7C4A88-3FE1-460E-94CB-3C92C9B99DA3Q36056076-05467425-E90E-4F77-8C67-3AF6859DF086Q36399139-47E84BB3-F22E-45AB-BE8E-E9548657626AQ36708245-C035C596-5959-4365-B2C7-75870E0D9911Q36762130-970735EA-CC84-4B7C-A065-C73C0AB2577CQ36848975-BC13889A-45A1-4CD5-9177-E96F2A81F6E1Q36875670-11C9EE74-F930-4766-A663-65DAD136F95EQ36997013-8AF70AF4-0DBD-4C3E-B457-13E51821E782Q37226231-CD04F272-5F5B-41DA-8C7B-D1AAA04A079DQ37435652-80C17690-7819-4B97-B5D0-7246B3212854Q37523542-BF08D148-F227-46BC-B297-1302D87C4B12Q37597763-51F88DA7-5071-418A-94F3-B450102719A8Q37689986-458C2A0C-2579-4394-BE45-EC6EE0F33FB9Q37752443-F3F620E9-F2B9-46A7-9D6C-37520918FFC1Q37823576-94EB8BA6-5A76-4610-B2A3-310E5605616BQ37848125-04D90EBF-A73F-41A6-9E33-6D9795964142Q37944951-6B0F30B5-9282-43D9-873F-498E083CA32C
P2860
Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors.
@en
Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors.
@nl
type
label
Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors.
@en
Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors.
@nl
prefLabel
Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors.
@en
Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors.
@nl
P2093
P1433
P1476
Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors.
@en
P2093
E Jenny Heathcote
Mario Ostrowski
Sharif B Missiha
P304
P356
10.1053/J.GASTRO.2008.02.069
P407
P577
2008-05-01T00:00:00Z